Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00791934 · ClinicalTrials.gov registry record · NA
Clinical Study of Safety and Efficacy for the Relieva Stratus With Elution of Triamcinolone Acetonide
A NA study, sponsored by Integra LifeSciences Corporation.
- Completed
- Registry status
- NA
- Development phase
- 63
- Enrollment target
NCT00791934 is a NA study that has completed, run by Integra LifeSciences Corporation. The registered enrollment target is 63 participants.
The verdict
NCT00791934, a NA study, has completed, sponsored by Integra LifeSciences Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 63 participants
- Enrollment target
Study Summary
Study Design: A non-randomized, multi-center, prospective, clinical study intended to evaluate the safety and efficacy of treating the ethmoid sinuses with the Ethmoid Sinus Spacer and Access System used for the local delivery of Triamcinolone Acetonide, over a period of 28 days.
Interventions
- DEVICE Stratus Microflow Ethmoid Spacer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2008-08 |
| Est. Completion | 2011-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00791934
The ClinicalTrials.gov registry entry for NCT00791934 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Integra LifeSciences Corporation, which has 60 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Stratus Microflow Ethmoid Spacer is the first listed.
NCT00791934 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00791934 about?
NCT00791934 is a clinical study titled "Clinical Study of Safety and Efficacy for the Relieva Stratus With Elution of Triamcinolone Acetonide". Study Design: A non-randomized, multi-center, prospective, clinical study intended to evaluate the safety and efficacy of treating the ethmoid sinuses with the Ethmoid Sinus Spacer and Access System used for the local delivery of Triamcinolone Acetonide, over a period of 28 days.
What is the current status of trial NCT00791934?
This trial is currently completed. It is a NA study. The enrollment target is 63 participants. The study started on 2008-08. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00791934?
The interventions under investigation include: Stratus Microflow Ethmoid Spacer (DEVICE).
Who is sponsoring clinical trial NCT00791934?
This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.